Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model

International Journal of Cancer

Volumn 104, Issue 3, 2003, Pages 376-379

  Breeman, Wouter A P ^a   Mearadji, Amir ^a   Capello, Astrid ^a   Bernard, Bert F ^a   Van Euck, Casper H J ^a   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

DOTA tate; Liver micrometastases; Lu 177; Peptide receptor radionuclide therapy; Somatostatin receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTATE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE] LUTETIUM LU 177; OCTREOTIDE; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE] YTTRIUM Y 90; PENTETREOTIDE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG RECEPTOR BINDING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LETHARGY; LIVER METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCINTIGRAPHY; TOXICITY; TUMOR GROWTH; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS, EXPERIMENTAL; LUTETIUM; MALE; OCTREOTIDE; RADIOISOTOPES; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0037431425     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10952     Document Type: Article

References (29)

1. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992;43:27-35.
2. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-5.
3. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9.
4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
5. Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Anti-proliferative effect of radiolabeled octreotide in a metastases model in rat liver. Int J Cancer 1999;81:767-71.
6. Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, de Jong M, Jamar F, Pauwels S. The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000;153:1-13.
7. 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998;4:94-102.
8. 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J 2000;93:809-11.
9. 111In-Octreotide therapy in patients with disseminated neuroendocrine tumors. Nucl Med Commun 2000;21:97-102.
10. Bernhardt P, Benjegard SA, Kolby L, Johanson V, Nilsson O, Ahlman H, Forssell-Aronsson E. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001;51:514-24.
11. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, Maecke HR, Jermann E, Robertson C, Fiorenza M, Tosi G, Paganelli G. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26:877-86.
12. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5.
13. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Brand F. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phel-Tyr3-octreotide. Eur J Nucl Med 2001;28:426-34.
14. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DT-PAo]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
15. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902-9.
16. Bernard BF, Krenning E, Breeman WA, Visser TJ, Bakker WH, Srinivasan A, de Jong M. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabeled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 2000;21:1079-85.
17. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33.
18. de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841-6.
19. Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 1984;33:689-92.
20. Erion J, Bugaj JE, Schmidt MA, Wilhelm RR, Srinivasan A. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model. J Nucl Med 1999;40:223.
21. de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE, Macke HR, Krenning EP. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41.
22. de Jong M, Bernard BF, De Bruin E, Van Gameren A. Bakker WH, Visser TJ, Macke HR, Krenning EP. Internalization of radiolabeled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283-8.
23. Andersson P, Forssell-Aronsson E, Johanson V, Wangberg B, Nilsson O, Fjalling M, Ahlman H. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phel-ocrreotide. J Nucl Med 1996;37:2002-6.
24. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, Ensing GJ, Lamberts SW, Krenning EP. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995;36:623-7.
25. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Macke HR, Krenning EP. Tumor uptake of the radiolabeled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693-8.
26. Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Miller LS, Houchens D, Cheng R, Kaplan D, Goeckeler W. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. Cancer Res 1991;51:2889-96.
27. 131]MIBG) in combination with other agents. Eur J Cancer. 1999;35:1171-3.
28. Slooter GD, Aalbers AG, Breeman WA, Hiemstra CA, Marquet RL, Krenning EP, Van Eijck CH. The inhibitory effect of radiolabeled octreotide on intrahepatic tumor growth after partial hepatectomy. J Nucl Med 2002;43:1681-7.
29. Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001;94:873-7.